Impact on bone microarchitecture and failure load in a patient with type I Gaucher disease who switched from Imiglucerase to Eliglustat
Gaucher disease (GD; OMIM 230800) is a lysosomal storage disorder caused by a deficiency in acid beta-glucosidase as a result of mutation in the GBA gene. Type 1 GD (GD1) is the most common form and its clinical manifestations include severe hematological, visceral and bone disease. The goal of dise...
Main Authors: | Karamjot Sidhu, Steven K. Boyd, Aneal Khan |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-09-01
|
Series: | Molecular Genetics and Metabolism Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2214426920300525 |
Similar Items
-
A Japanese Patient with Gaucher Disease Treated with the Oral Drug Eliglustat as Substrate Reducing Therapy
by: Naoto Komada, et al.
Published: (2021-09-01) -
The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients
by: Patrick Deegan, et al.
Published: (2021-02-01) -
Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)
by: Derralynn A. Hughes, et al.
Published: (2022-08-01) -
Case report of unexpected gastrointestinal involvement in type 1 Gaucher disease: comparison of eliglustat tartrate treatment and enzyme replacement therapy
by: Yoo-Mi Kim, et al.
Published: (2017-05-01) -
Profile of eliglustat tartrate in the management of Gaucher disease
by: Sechi A, et al.
Published: (2016-01-01)